Obesity, a condition that is becoming a leading cause of human morbidity and mortality, is among the global healthcare challenges of the 21st century. Specifically, obesity is a major risk factor for cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease and some forms of cancer. New and emerging medicines show unprecedented efficacy in promoting weight loss. This symposium will fuse existing knowledge with the latest discoveries in the underpinning mechanisms of obesity drug action, potential health benefits beyond weight loss, improving the quality of weight loss and minimizing side effects, and preserving muscle mass during weight loss. Recent advances in diverse combination therapies, new biology discoveries of glucagon and amylin and in leveraging enteroendocrine cell secretion will also be presented. The application of cutting-edge drug discovery approaches and the clinical relevance of basic science discoveries to obesity research will also be highlighted. In combination with a joint symposium on Cardiometabolism in Health and Disease, this exciting program will bring together breaking research from both basic science and translational realms on the treatment of obesity and cardiometabolic disease to foster cross-disciplinary insights, discovery and collaborations.